Q-omics provides the consensus-scored TMEM168 profile across patient tissues and cancer cell-line models. TMEM168 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TMEM168 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, TMEM168 RNA expression shows 20,923 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where TMEM168 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM168 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM168 survival associations across molecular data types. TMEM168 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM168 RNA expression–survival associations across cancer types. High TMEM168 expression shows unfavorable associations in UVM, KICH and LGG, but favorable associations in KIRC, UCS and LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TMEM168 RNA expression.
This table summarizes TMEM168 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TMEM168. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM168 shows lower tumor expression in THCA, KIRC and KICH and higher tumor expression in LIHC, STAD and CHOL. The THCA box plot shows higher TMEM168 RNA expression in normal versus tumor tissue (log2 FC = −0.855, t-test p < 0.001).
This table shows molecular features associated with TMEM168 in patient tissues and cancer cell lines. In patient samples, TMEM168 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM168 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
